Benzonatate Modified Release Tablets via Reverse Enteric Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current benzonatate compositions are prone to undesirable side effects such as rapid absorption in the oral mucosa, leading to numbness and potential pulmonary aspiration due to their immediate release nature, which can result in overdose when chewed or dissolved in the mouth, necessitating a modified release formulation that avoids buccal cavity release.
Innovation Solution
Development of modified release solid compositions comprising benzonatate in a matrix with a homogenous solid dispersion and a reverse enteric coating, utilizing adsorbates like calcium silicate and hydrophobic waxes to control the release profile, ensuring no more than 50% release within 1 hour and substantial release only after 6 hours, thereby minimizing buccal cavity exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release composition is used, then rapid therapeutic effect is achieved, but rapid absorption in oral mucosa causes numbness and potential pulmonary aspiration
Solution Approach 1:
The patent applies preliminary action by pre-coating the benzonatate core with an enteric coating before administration. This coating prevents premature release in the buccal cavity and esophagus, ensuring the drug is protected until it reaches the stomach where acidic conditions trigger release. This resolves the contradiction by maintaining rapid therapeutic effect while preventing harmful oral mucosa absorption through advance protective措施.
Solution Approach 2:
The enteric coating acts as an intermediary barrier between the benzonatate core and the oral mucosa. This intermediate layer prevents direct contact and absorption in the mouth and throat, while allowing controlled release in the stomach. The coating material serves as a mediator that enables the drug to achieve therapeutic effect without causing the harmful numbness and aspiration risks associated with immediate release.
2Productivity
If immediate release composition is used, then full drug release occurs quickly, but overdose risk increases when chewed or dissolved in mouth
Solution Approach 1:
The enteric coating is applied in advance to the benzonatate core, creating a protective barrier that controls the timing and location of drug release. This preliminary protective measure ensures that even if the patient chews or dissolves the tablet in the mouth, the drug remains encapsulated and cannot be rapidly absorbed, thereby preventing overdose while maintaining the ability for complete drug release in the stomach.
Solution Approach 2:
The enteric coating serves as an intermediary protective layer that physically separates the active drug from the oral cavity. This intermediate barrier maintains drug stability and prevents premature release, ensuring that the full dose is only released in the appropriate environment (stomach acid), thus preventing overdose while preserving complete drug availability for therapeutic effect.
3Reliability
If multiple daily doses are administered, then therapeutic levels are maintained, but patient convenience decreases
Solution Approach 1:
The enteric-coated benzonatate composition enables continuous therapeutic action by ensuring complete and controlled drug release in the stomach, maximizing bioavailability from each dose. This continuous action profile allows the drug to maintain therapeutic levels more effectively, reducing the need for frequent dosing and improving patient convenience while preserving reliable therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified release compositions provide a stable and controlled release of benzonatate, reducing the frequency of doses and minimizing side effects by maintaining therapeutic levels for 10-12 hours with reduced absorption in the buccal cavity, thus enhancing patient convenience and safety.
Implementation Method 1
a reverse enteric coating over the benzonatate in a matrix wherein there is no more than about 50%, preferably less than about 40%, more preferably less than about 25%, of the benzonatate released from the composition within 1 hour
Implementation Method 2
benzonatate in a matrix wherein said matrix is a homogenous solid dispersion comprising (i) a benzonatate component and (ii) at least one pharmaceutically acceptable modified release pH-independent, hydrophilic or hydrophobic matrix-forming substance
Implementation Method 3
utilizing adsorbates like calcium silicate and hydrophobic waxes to control the release profile
Data Source
AI summary
A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.